Recent events
Recent events tied to this brand in public sources.
Back to profile30 entries · Page 2 of 2
2020
Lilly partners with Indiana health department on coronavirus testing
Eli Lilly partnered with the Indiana State Department of Health to accelerate coronavirus testing. Lilly’s scientists would facilitate SARS-CoV-2 testing at the company’s research laboratories, using samples from Indiana healthcare facilities.
2020
Lilly launches Reyvow migraine medicine
Eli Lilly launched Reyvow, an acute migraine medicine, after completion of a Drug Enforcement Administration review.
2020
Lilly sets Reyvow price at $640 per eight-pill pack
Lilly priced Reyvow at $640 per eight-pill pack. The article notes that patients' actual out-of-pocket costs may vary.
2020
Eli Lilly announces discounted insulin pens
Eli Lilly announced plans to offer discounted versions of two insulin pens for 50 percent less than their current list price; the pens were expected to be available by mid-April.
2020
Eli Lilly announces plan to acquire Dermira
Eli Lilly announced that it would acquire Dermira for $1.1 billion. The article reports the announcement as having come on Friday.
2019
Drugmakers agree to reduce prices of some medicines in China
Chinese regulators said pharmaceutical companies, including Roche and Novartis, agreed to reduce the China prices of some newer medicines by an average of 61% to enter the national medical insurance reimbursement list.
2019
Harris County files insulin price-fixing lawsuit
Harris County sued insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with pharmaceutical benefit managers Aetna Rx, CVS Caremark, Express Scripts and OptumRx, alleging they colluded to drive up insulin prices. The county seeks to recover more than $27 million it says it has paid to the companies.
2019
Eli Lilly reports third-quarter 2019 results
Eli Lilly announced its third-quarter 2019 financial results, reporting revenue of $5.477 billion and reported earnings per share of $1.37.
2019
Eli Lilly raises 2019 EPS guidance
Eli Lilly announced that it had raised its 2019 EPS guidance to $8.59–$8.69 on a reported basis and $5.75–$5.85 on a non-GAAP basis.
2019
Eli Lilly announces Erl Wood research centre closure and potential redundancies
Eli Lilly announced that it would close its Erl Wood research centre in the UK, potentially resulting in 80 redundancies.